Arjo AB's Total Assets for the quarter that ended in Mar. 2026 was €1,436.9 Mil.
During the past 12 months, Arjo AB's average Total Assets Growth Rate was -0.80% per year.
During the past 3 years, the average Total Assets Growth Rate was -2.00% per year.
During the past 5 years, the average Total Assets Growth Rate was 2.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 1.90% per year.
During the past 13 years, Arjo AB's highest 3-Year average Total Assets Growth Rate was 4.10%. The lowest was -4.90%. And the median was 3.00%.
Total Assets is connected with ROA %. Arjo AB's annualizedROA % for the quarter that ended in Mar. 2026 was 2.85%. Total Assets is also linked to Revenue through Asset Turnover. Arjo AB's Asset Turnover for the quarter that ended in Mar. 2026 was 0.18.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Arjo AB's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Arjo AB Total Assets Related Terms
Arjo AB Total Assets Historical Data
* Premium members only.
The historical data trend for Arjo AB's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Arjo AB's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arjo AB (FRA:A39) has a Total Assets of €1,436.9 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Arjo AB and its competitors.
Is Arjo AB's Total Assets too high?
Arjo AB's current Total Assets is €1,436.9 Mil. Overall, Arjo AB has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's Total Assets compare to MCK and CAH?
Arjo AB's Total Assets of €1,436.9 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Distribution company?
A good Total Assets depends on the Medical Distribution industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Arjo AB and its competitors. Arjo AB's current Total Assets is €1,436.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (FRA:A39) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.21, compared to a current price of €2.41 — trading 24.9% below its estimated fair value. The current Total Assets is €1,436.9 Mil. Arjo AB's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Arjo AB (FRA:A39), the current Total Assets is €1,436.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arjo AB (FRA:A39) Overvalued in 2026?
Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued.
The current stock price of €2.41 is trading 24.9% below its estimated GF Value™ of €3.21.
GuruFocus considers Arjo AB to be Modestly Undervalued.
Key valuation signals for FRA:A39:
Total Assets: €1,436.9 Mil
GF Value™: €3.21 vs. price of €2.41 (24.9% below fair value)
No single metric tells the full story. See the FRA:A39 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
74GF Score
Get the complete analysis for FRA:A39
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A39 has been successfully added to your 
